Despite a wealth of treatments for relapsing remitting multiple sclerosis (RRMS), developing effective treatments for progressive forms of MS remains a significant unmet need. Because the neurogenerative component of the disease often dominates over the inflammatory component in PMS, imaging outcomes commonly used in RRMS clinical trials, such as new T2 lesions and gadolinium-enhancing lesions, are insensitive outcomes in PMS. In fact, the optimal primary outcome measure for phase II and phase III PMS clinical trials is not well established. Robust outcomes to measure progression of disability would significantly aid in the rapid evaluation of treatments with potential neuroprotective effects in MS.Atrophy is considered a substrate for clinical disability and cognitive dysfunction. Advances in methodology of imaging segmentation tools allow for evaluation of specific brain regions that are preferentially affected in MS, including the thalamus, corpus callosum, and cerebellum. This proposal addresses the FY17 MSRP Focus Area of Biological Correlates of Disease Activity and Progression in MS by evaluating the ability of these regional outcome measures to assess neuroprotective therapies in MS.
|Ani Elyoan||Staff 1||Research Assistant i|